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ABSTRACT
Background: Several nonviral vectors including L-PEI confer a pronounced lung
tropism to plasmid DNA when injected in the mouse tail vein in a non-ionic solution.
Methods and Results: We have optimized this route by injecting 50 µg DNA with
excess L-PEI (N/P=10) in a large volume of 5% glucose (0.4 ml). In these conditions,
1-5% percent of lung cells were transfected (corresponding to 2 ng luciferase/mg
protein), the other organs remaining essentially refractory to transfection (1-10 pg
luciferase/mg protein). Beta-galactosidase histochemistry confirmed alveolar cells,
including pneumocytes, to be the main target, thus leading to the puzzling observation
that the lung microvasculature must be permeable to cationic L-PEI/DNA particles of
ca. 60 nm. A smaller injected volume, premixing of the complexes with autologous
mouse serum, as well as removal of excess free L-PEI, all severely decreased
transgene expression in the lung. Arterial or portal vein delivery did not increase
transgene expression in other organs.
Conclusions: These observations suggest that effective lung transfection primarily
depends on the injection conditions: the large nonionic glucose bolus prevents
aggregation as well as mixing of the cationic complexes and excess free L-PEI with
blood. This may favour vascular leakage in the region where the vasculature is dense
and fragile, i.e. around the lung alveoli. Cationic particles thus can reach the
epithelium from the basolateral side where their receptors (heparan sulfate
proteoglycans) are abundant.
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INTRODUCTION
Non-viral vectors continue to arouse interest because of their safety and low
immunogenicity profiles. Major drawbacks still remain, such as low efficacy and
short duration of transgene expression. However, in several recent reports describing
cationic lipid formulations that were optimised for systemic delivery [1-3] by
exploring either new structures [4, 5], formulation conditions [6-9] or additives [10-
12], promising expression levels were reached. Polylysine, a member of the other
class of synthetic vectors, has been extensively tested for systemic gene delivery as
well [13, 14], especially for targeting the liver [15]. The low efficacy of intracellular
release of polylysine/DNA complexes [16] has impeded further development. The
discovery that some cationic polymers, such as polyethylenimine (PEI) [17] and
polyamidoamine dendrimers [18, 19], facilitate endosomal release, may lead to a
revival of this class of vectors. Indeed, recent work shows that PEI is a good vehicle
for polynucleotide delivery in vivo following lung instillation [20], kidney perfusion
[21], intracerebral injection [17, 22, 23] or systemic delivery to the lung [24] or to the
liver [25, 26]. Among the various molecular weights (700 – 8.105 Da) and topological
isomers (branched or linear skeleton) available for PEI, the linear 22 kDa compound
(L-PEI) has shown the most favourable properties. Indeed, L-PEI-mediated
transfection remains effective in serum [27, 28] and, when formulated with DNA in
low salt, leads to small (ca. 60 nm) particles that are less prone to size-restricted
diffusion in vivo [23].
In this report, L-PEI/plasmid complexes were injected into the venous and arterial
blood stream. Analysis of the spatial and temporal expression profiles showed the lung
to be the only organ significantly (though transiently) transfected. Histochemistry
revealed the pattern of cells expressing the transgene. Finally, several additional
experiments allow us to propose a hypothesis for the lung expression tropism that is
generally observed following tail vein DNA delivery with cationic vectors.
MATERIALS AND METHODS
Intravenous injection of the complexes into the tail vein and luciferase expression
pCMVLuc and L-PEI (Exgen 500, Euromedex, Souffelweyersheim, France;
N/P=10) were diluted separately in 200 µl of 5% glucose. After 10 min, solutions were
mixed, homogenised immediately and left for 10 min. Female Balb/C mice (5 weeks
old, CERJ, Le Genest-St-Isle, France) were placed in a restrainer and 400 µl of
PEI/DNA complexes/mouse (n>4) were injected in the tail vein within 30 sec, using
a 1/2 inch 26-gauge needle and a 1 ml syringe. Animals were anaesthetised after 24 h
by breathing ether and decapitated to drain the blood off. Heart, lung, spleen, kidneys
and 120-140 mg of the liver were collected in 1.5 ml Eppendorf tubes. The tissues
were rapidly frozen in dry ice, then in liquid nitrogen. After thawing, samples were
transferred into 10 ml plastic tubes containing 1 ml precooled lysis buffer (Promega,
Cergy Pontoise, France) supplemented with a protease inhibitor cocktail (1 ml/20 g
tissue, Sigma, Saint Quentin Fallavier, France). Tissues were homogenized with an
Ultra-Turrax T25 (Janke & Kunkel, Staufen, Germany) at 20,000 rpm for 30 s and
subjected to three (-80°C/37°C) freeze/thaw cycles. The homogenates were
centrifuged at 14,000g for 4 min at 4°C and 20 µl supernatant aliquots were assayed
for luciferase activity using a commercial kit (Promega) and a luminometer (Biolumat
LB 9500, Berthold, Paris, France). Results were expressed as light units integrated
over 10s ± s.d., per mg of cell protein using the BCA assay (Pierce, Paris, France).
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Luciferase content was determined from a standard curve obtained with Photinus
pyralis firefly luciferase (Boehringer Mannheim, Meylan, France) using the equation
ng luciferase = (RLU + 1.25X106) / (5.03X107).
b -Galactosidase histochemistry in the lung
L-PEI/DNA complexes were prepared with 50 µg pCMVßgal (N/P=10) and
injected in the tail vein as described above. Mice were sacrificed 24h later by
decapitation. After windowing the right atrium, a plastic catheter was placed inside
the ascending aorta via the left ventricle. Mice were first perfused at room temperature
with 5 ml PBS containing 1% glutaraldehyde, 2% paraformaldehyde, 0.01% sodium
deoxycholate and 0.02% Nonidet P-40 (PBS fixative solution), and then for 3 h at 4°C
with the same solution. A last perfusion was performed with PBS only for 1 h. Lungs
were collected and incubated at 37°C for 24 h in a solution containing 1 mg/ml X-gal
(stock solution in dimethylformamide at 40 mg/ml, Euromedex), 5 mM K3Fe(CN)6,
5 mM K4Fe(CN)6, 2 mM MgCl2 in 10 mM PBS, pH 7.4. The lungs were washed
three times with 3% DMSO in PBS and photographed before being embedded in
paraffin. Continuous 6 µm-thick sections were cut off, mounted on glass slides, and
counterstained with nuclear red.
Measurement of zeta potentials and of the amount of PEI in the complexes
DNA (40 µg pCMVLuc) and the desired amount of L-PEI were each diluted in 500 µl
of a 5% glucose or a 150 mM NaCl solution. After 10 min, solutions were mixed,
homogenized and left for 10 min at room temperature. The zeta potential of the
complexes was measured electrophoretically [32] using a Zetasizer 3000 (Malvern
Instrument, Orsay, France). In order to measure the fraction of PEI present in the
PEI/DNA complexes, PEI was labelled with fluorescein isothiocyanate (Sigma) in a
0.2 M borate buffer, pH 8.4. The conjugate was purified by gel filtration on a PD10
column (Sephadex G-25 M, Pharmacia Biotech, Sweden) in water. The concentration
of PEI amine functions (N) was determined with the ninhydrin assay. The level of
fluorescein conjugation per amino group of PEI was 1% as measured by absorption
spectroscopy at 495 nm. Complexes were prepared with 50 µg DNA and the desired
amount of PEI-fluorescein in a total volume of 500 µl 5% glucose. The solution of
PEI/DNA complexes was filtered by centrifugation (500 g, 20 min, 20°C) through a
Centricon-100 membrane (100,000 Da cut-off, Amicon, Beverly, MA). The amount of
free PEI-fluorescein in the filtrate was determined by absorbance at 495 nm, from
which the fraction of PEI that was associated with DNA was calculated.
RESULTS
Calibration of reporter gene expression and selection of the cationic vector
In vivo, the most commonly used reporter genes are those of the firefly luciferase
for assessing overall transfection levels, and of the bacterial ß-galactosidase for
characterizing the percentage and type of transfected cells. Photometric detection of
luciferase activity is so sensitive that it may lead to misleading conclusions.
Histochemical tissue analysis following X-gal staining, while meaningful, is not
convenient for percentages <0.1%. As a prerequisite to animal experiments, we first
decided to set up a conversion chart between these reporter genes, using data obtained
for transfection of various cell types in vitro with a cationic lipid (Transfectam) and a
cationic polymer (PEI). Luciferase levels, that were expressed as relative light units
(RLU)/mg total cell proteins[27], which is apparatus-dependent, were also plotted as
nanogram reporter protein per milligram cell protein, a dimensionless number (Figure 1).
Comparison of the percentage of ß-galactosidase-positive cells with overall
transfection levels showed that when virtually all cells were transfected, they
produced ca. 100 ng luciferase/mg cell protein, i.e. 0.01% of their protein mass as
exogeneous protein. The interesting transfection levels were found within the range
0.1-100 ng luc/mg protein (107-1010 RLU/mg protein), where the percentage of ß-
gal-positive cells (0.5-100%) was roughly proportional to the overall luciferase level.
The lower limit of this range is still >1,000-fold over background (Figure 1), which
highlights the extreme sensitivity of photonic detection: a single transfected cell can
be detected among 107 cells! As a take-home rule, 1 ng luc / mg protein thus
corresponds to 1% transfected cells. This gives an idea of luciferase levels to be
reached in animals.
With regard to the vector, several polyethylenimines are available [29, 30], that
differ from one another in molecular weight (15-1,000 kDa) and in topology (linear
or branched). While most were of comparable efficacies in vitro, only the linear 22
kDa polymer (L-PEI) remained insensitive to up to 30% serum during transfection
[28]. In addition, preliminary in vivo screening of polymers showed branched
PEI to be very toxic after tail vein injection: animals died within a few hours,
presumably as a consequence of the numerous microemboli found in their lung tissues.
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Figure 1. A conversion chart between overall transfection levels (as measured by
luciferase activity) and the percentage of ß-galactosidase-positive cells. 
Cells were transfected in 24-well plates using 2µg DNA (pCMVluc or pCMVßgal) complexed
with a cationic lipid (Transfectam, N/P=6) or with a cationic polymer (PEI, N/P=9). Luciferase
activity after 24 h was normalised per mg of cell protein as described in Materials and
Methods. Alternatively, cells that were transfected with PEI/pCMVßgal were fixed and counted






















































































L-PEI was not lethal when formulated in isotonic NaCl, but led respectively to one
thousand- and ten-fold lower expression than with isotonic glucose in the lung and in
the heart; other organs were not affected. We thus used L-PEI/DNA complexes in 5%
glucose [23, 24, 31] for all experiments. In these salt-free conditions, complexes remain
small because electrostatic repulsion is stronger than Van der Waals attraction [32].
Body distribution of transgene expression following tail vein injection
Increasing amounts of pCMVluc/L-PEI complexes in 400 µl 5% glucose were
injected within 30 seconds in the tail vein of BalbC mice. The amount of luciferase
found in the lung, heart, spleen, liver and kidney after 24 hours increased 50-100 fold
when the amount of DNA was increased from 20 µg to 50 µg (Figure 2). Higher
amounts (100 µg) became toxic (only two animals survived out of four) and did not
significantly increase transfection.
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Figure  2 . Intravenous injection of L-PEI/DNA complexes in the mouse leads to
detectable reporter gene expression in various organs. 
Expression was ca. one hundred-fold higher in the lung than in the other organs. Mice
injected with up to 50 µg DNA complexed with L-PEI showed no signs of toxicity. Injection of
100 µg DNA complexed with PEI led to 50% mortality within 24 hours. Autopsy showed
frequent scattered red embolism centers in the lung and necrosis centers in the liver.




















To assess the influence of the amount of L-PEI on gene delivery, 50 µg
pCMVluc were injected with increasing amounts of cationic polymer (Figure 3).
Since cell entry relies on electrostatic interaction of the complexes with the cell
surface [33, 34], it is convenient to express the PEI/DNA ratio as amine over
phosphate. Complexes that were electroneutral in physiological salt concentration
(N/P=3, see zeta potentials below) did not transfect significantly better than naked
DNA (N/P=0). Increasing N/P ratio (4 to 10) led to increasing levels of transfection
in all organs. Very high ratio (N/P=20, not shown) were lethal. Interestingly, after
the onset of transfection (N/P>3, Figure 3), the amount of luciferase found in
the lung was always a hundred-fold higher than that found in the other organs.
Such pronounced lung expression tropism following tail vein injection has been
described by several authors, irrespective of the cationic lipid or polymer formulation
used [2, 6, 9, 10, 24, 35]. According to the chart of Figure 1, transfection levels found
in the other organs are very low (although well over background). Luciferase levels
found in the lung (2 ng/mg protein), however, corresponded to the range of one
percent transfected cells (see previous paragraph). Although transgene expression
decreased by two orders of magnitude after 2 days (Goula et al. [24] and data not
shown), presumably because of cytotoxicity, it was therefore of interest to find out
which were the transfected cell types. 
Histochemical analysis of transgene expression in the lung
Tail vein injection was repeated with 50 µg pCMVßgal and L-PEI (N/P=10).
Organs were perfused and stained in toto with X-gal. As expected from the luciferase
experiments, only the lung tissue showed visible transgene expression. A control
experiment (Figure 4a) performed with pCMVluc/L-PEI complexes confirmed the
lung to be devoid of endogeneous ß-galactosidase staining after 24 h. In contrast,
macroscopic examination of a lung lobe from a mouse transfected with pCMVßgal
showed an intense blue staining that was evenly spread all-over the organ (Figure 4b).
Examination of thin sections under the microscope (Figure 4c) showed 1-5% of lung
cells to be transfected. This level is somewhat higher than that obtained by Goula et
al. [24] using 125 µg DNA and N/P=4. Transfection was restricted to the distal region
of the airway tree, in the vicinity of the alveoli. Epithelial cells of the small
conducting airways were not transfected (inset in Figure 4c). A closer (X400)
examination of the alveolar tissue sections showed that transfected cells were
essentially pneumocytes (Figure 4d) and some endothelial cells (inset in Figure 4d).
This histologic profile led to the conclusion that the lung vascular endothelium was
permeable to PEI/DNA particles as large as 60 nm.
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Figure 3. Gene delivery in vivo requires cationic complexes. 
L-PEI/DNA complexes were prepared with 50 µg pCMVluc and various amounts of L-PEI and
injected into the tail vein of mice (4<n<6) according to Materials and Methods. In physiological








































Why is transgene expression so high in the lung? 
Although nonlethal experimental conditions could be worked out, tail vein
injection of 0.4 ml (ca. 20% of the mouse total blood volume) transfection mix over
30 s with a 26-gauge needle may simultaneously occlude the tail vein blood
circulation during the injection procedure, push a glucose bolus throughout the
general circulation back towards the lung and eventually generate hydrostatic
pressure. Besides the known effects of pressure on vascular leakage and transfection
[36-39], this protocol could prevent most of the L-PEI/DNA complexes from binding
to blood proteins responsible for decreased cell-surface binding. To test this
hypothesis, the L-PEI/DNA complexes in 0.2 ml were incubated for 15 min with 0.2
ml autologous mouse serum prior to injection. Although ionic strength was increased,
complexes remained small due to coating by serum proteins [31] hence animals
histology showed no sign of microemboli (not shown). The lung expression tropism,
however, was lost (Figure 5). In another experiment where complexes were injected in
a fourfold smaller volume, expression in the lung was decreased eightfold (Figure 5).
These findings thus emphasize the critical importance of the injection conditions in
successful gene delivery to the lung. 
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Figure 4. Expression pattern of ß-galactosidase in the lung
A) Control experiment: section of a Xgal-incubated lung after transfection with L-PEI/pCMVluc
complexes (magnification X100). B) After ß-galactosidase gene delivery, the left lung lobe
shows intense and evenly distributed blue staining. C) Section through the alveolar region
shows 1-5% ßgal-positive cells (X100); inset: epithelial cells of the small conducting airways
are not transfected. D) Higher magnification of transfected alveoli (X400) and of a capillary
(inset X800). 
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Figure 5. Gene delivery to the lung is decreased by tail vein injection of L-PEI/DNA
complexes in a smaller volume or by mixing with serum. 
Plasmid (50 µg pCMVLuc) and L-PEI (N/P=10) were each diluted separately in 50, 100 or 200 µl
5% glucose. After 10 min, solutions were mixed, homogenized immediately and left for 10 min,
thus giving L-PEI/DNA complexes in final volumes of 100, 200 and 400 µl. Complexes in 200
µl 5% glucose were mixed with 200 µl autologous mouse serum and incubated for 10 min.
Complexes were injected in the tail vein (n = 3). Organs were collected 24h later and
































Another crucial and eloquent factor is the L-PEI/DNA (N/P) ratio: the onset of lung
transfection (N/P>3, Figure 3) correlates well with a particle surface charge (zeta
potential, Figure 6) becoming positive when measured in 150 mM NaCl rather than in
glucose. This is evidence that complexes experience a physiological salt environment
after vascular escape. Furthermore, transfection of all organs is very much increased
when N/P increases from 4 to 10 (a similar trend was found for cationic lipids [40],
although the surface charge (Figure 6) and size [23] of the complexes remain constant.
This latter remark led us to measure the amount of PEI that was effectively bound to
DNA. Indeed, in the asymptotic zeta potential regime, most of the extra PEI is not
associated with the complexes (Figure 6). The beneficial effect of excess free PEI on
transfection is, however, very pronounced (Figure 3). In an attempt to assess its exact
role, we preinjected the mice with approximately the amount of free PEI found in
solutions where N/P=10 (i.e. corresponding to N=6) and injected the cationic
complexes made at N/P=4 some 15 min later: transfection results in all organs (not
shown) were comparable to those found for N/P=4 (see Figure 3), showing that
excess PEI, to be beneficial, must be present simultaneously with the complexes.
We next checked whether specific lung expression could be redirected to another
organ. Injection of L-PEI/pCMVluc complexes into the portal vein decreased lung
expression fifteen-fold (Figure 7); injection into the left ventricle of the heart
decreased lung expression 80-fold. Remote injection thus decreased the lung tropism,
in agreement with the aforementioned hypothesis. However portal vein injection did
not increase luciferase expression in the liver, nor did intracardiac injection increase
expression in organs with a direct arterial blood supply. 
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Figure 7. Systemic gene delivery leads to scattered expression profiles. 
L-PEI/DNA complexes were prepared in 400 µl of 5% glucose with 50 µg pCMVLuc (N/P=10).
For tail vein injection, see Materials and Methods. For portal vein injection, mice were
anaesthetised by intramuscular injection of ketamine hydrochloride (500 µg/20 g of body
weight). The mesenteric vein was surgically exposed by a 1.5 cm abdominal midline incision
and complexes diluted to 1 ml with 5% glucose were injected in the portal vein over at least
one minute, using a 1/2 inch 30-gauge needle and a 1 ml syringe (n=3). For intracardiac
injection, mice were anaesthetised as described above. A median sternal incision of the skin
exposed the left thorax. A left ventricular puncture was performed between the 4th and 5th
intercostal space on the left clavicular midline using a 1/2 inch 30-gauge needle and a 1 ml
syringe; complexes were injected over 30s (n=3). Organs were collected and processed as
























Tail vein Portal vein Left ventricle
Figure 6. Surface charge (zeta potential, left axis) of L-PEI/DNA complexes and
percentage of cationic polymer present in complexes formed in 5% glucose (right axis)
as a function of the PEI to DNA ratio (N/P).
In a nonionic glucose solution, the surface charge of the complexes reaches a limiting
cationic value for N/P of 2-3. Accordingly, the amount of PEI in the complexes should then
remain constant, the extra amount of PEI being free polymer in solution. This was roughly
verified, e.g. for N/P=10, 30% of PEI is complexed, i.e. in the complexes, N/P has reached




































Altogether, these results show that organs are generally not significantly
transfected by systemic delivery of cationic complexes. Only their vascular
endothelium is accessible to the particles, and primary endothelial cells are known to
be difficult to transfect [27], presumably because they lack the desired receptor
(heparan sulfate proteoglycan HSPG [34, 41, 42]) on their apical membrane [43]. The
pharmacokinetics of cationic DNA complexes distribution has shown that cationic
DNA complexes are essentially taken up by the lung and the liver  [1, 5, 44]. Liver
uptake takes place in Kupffer cells [44], yet macrophages too are difficult to transfect
[5]. The lung endothelium represents a large surface that may be mechanically and
osmotically fragile since the alveolar endothelial/epithelial junction must be thin for
fast gas exchange to occur. In the particular experimental setup described above, the
small L-PEI/DNA complexes present in nonionic glucose solution may thus escape
from a transiently leaky vasculature and reach the neighbouring polarized cells from
the basolateral side where the anionic HSPG receptor is expressed [45], hence the
exceptionally high level of transfection found in the lung.
Unfortunately, this surprising result requires conditions that may never be scaled
up to large animals (it would correspond to a 1 liter glucose bolus injected within
minutes in a human; but see also ref [38]). More reasonable goals for systemic
delivery of particulate DNA vectors are targeting of mitotic integrin-expressing
endothelial cells of tumors [46], or of asialoglycoprotein-expressing hepatocytes [47,
48] that are accessible through the fenestrated liver endothelium. These targets require
the complexes to remain active and small in the blood, an objective which is being
actively pursued by several groups [10, 12, 49, 50].
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